Treatment options for refractory depression

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 4, 1999, Pages 57-63

  Shelton, Richard C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMINOGLUTETHIMIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CARBAMAZEPINE; CLOZAPINE; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; KETOCONAZOLE; LIOTHYRONINE; LIOTHYRONINE SODIUM; METHYLPHENIDATE; METYRAPONE; MIRTAZAPINE; NORADRENALIN; PAROXETINE; PHENELZINE; PINDOLOL; RISPERIDONE; SERTRALINE; VENLAFAXINE;

DECISION MAKING; DEPRESSION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; ELECTROCONVULSIVE THERAPY; HUMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; LITHIUM; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 0033063496     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51(6, suppl):39-47
2. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996;39:1-6
3. Mueller TI, Keller MB, Leon AC, et al. Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry 1996;53:794-799
4. McGrath PJ, Stewart JW, Nunes EN, et al. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. J Clin Psychiatry 1994;55:336-339
5. Phillips KA, Nierenberg AA. The assessment and treatment of refractory depression. J Clin Psychiatry 1994;55(2, suppl):20-26
6. Quitkin FM, McGrath JP, Stewart JW, et al. Chronological milestones to guide drug change: when should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53:785-792
7. Keller MB. The difficult depressed patient in perspective. J Clin Psychiatry 1993;54(2, suppl):4-8
8. Shelton RC. Treatment-resistant depression: therapeutic options. Medscape Mental Health [serial online]. 1996:1(2). Available at http://www. medscape.com/Medscape/MentalHealth/1996/v01.n02/mh65.shelton/ mh65.shelton.html
9. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression. Arch Gen Psychiatry 1986;43: 1155-1121
10. Reimherr FW, Woods DR, Byerley B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984;20:70-72
11. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097
12. Cole JO, Schatzberg AF, Sniffin C, et al. Trazodone in treatment-resistant depression: an open study. J Clin Psychopharmacol 1981;1:49-54
13. Nolen WA, Van De Putte JJ, Dijken WA, et al. Treatment strategy in depression, I: nontricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988;78:668-675
14. Peselow ED, Filippi AM, Goodnick P, et al. The short- and long-term efficacy of paroxetine HCL, B: data from a double-blind crossover study and from a year-long trial vs imipramine and placebo. Psychopharmacol Bull 1989;25:272-276
15. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 1992;28:253-256
16. Wemicke JF, Dunlop SR, Dornseif BE, et al. Fixed dose fluoxetine therapy for depression. Psychopharmacol Bull 1989;23:164-168
17. Amin M, Lehmann H, Mirmiran J. A double-blind, placebo-controlled dose-finding study with sertraline. Psychopharmacol Bull 1989;25: 164-167
18. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53(2, suppl):21-26
19. Fava M, Rosenbaurn JF, Cohen L, et al. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord 1992;25:229-234
20. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-1374
21. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1992;14:419-423
22. de Montigny CF, Grunberg AF, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981;138:252-256
23. de Montigny CF, Codurnoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40:1327-1334
24. Price LH, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 1983;140:318-322
25. Thase ME, Kupfer DJ, Frank E, et al. Treatment of imipramine-resistant recurrent depression, II: an open clinical trial of lithium augmentation. J Clin Psychiatry 1989;50:413-417
26. Delgado PL, Price LH, Charney DS, et al. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;15:55-60
27. Loosen PT, Shelton RC. Hormonal potentiation of antidepressants. In: Amsterdam J, ed. Antidepressant Therapy. New York, NY: Marcel Dekker; 1988:241-253
28. Charney DS, Miller HL, Licinio J, et al. Treatment of depression. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995:588-601
29. Jolfe RT, Singer W, Levin AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393
30. Baron BM, Ogden A, Seigel BW, et al. Rapid down-regulation of β-adrenoreceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988;154:125-134
31. Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts non-responders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-449
32. Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565
33. Eisen A. Fluoxetine and desipramine: a strategy for augmenting antidepressant response. Pharmacopsychiatry 1989;22:272-273
34. Nelson JC, Mezure CM, Bowers MB, et al. A preliminary open study of the continuation of flucxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
35. Zajecka JM, Jeffriess H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 1995;56:338-343
36. Pande AC, Calarco MM, Grunhaus LJ. Combined MAOI-TCA treatment in refractory depression. In: Amsterdam JD, ed. Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression. New York, NY: Raven Press; 1991:115-122
37. Davidson J, McLeod M, Law-Yone B, et al. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry 1978;35:639-642
38. Kahn D. Carbamazepine and other antiepileptic drugs in refractory depression. In: Roose SP, Glassman AH, eds. Treatment Strategies for Refractory Depression. Washington, DC: American Psychiatric Press; 1990:143-167
39. Ketter TA, Post RM, Parekh PI, et al. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J Clin Psychiatry 1995; 56:471-475
40. Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132
41. Klaiber EL, Broverman DM, Vogel W, et al. Estrogen therapy for severe pereistent depression in women. Arch Gen Psychiatry 1979;36:550-557
42. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-220
43. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993; 54:269-271
44. Artigas F, Romero L, de Montigny C, et al. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996;19:378-383
45. Murphy BE, Dhar V. Ghardirian AM, et al. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 1991;11:121-126
46. Amsterdam JD, Rosenzweig M, Mozley PD. Assessment of adrenocortical activity in refractory depression: steroid suppression with ketoconazole. In: Nolen WA, Zohar J, Roose SP, et al, eds. Refractory Depression: Current Strategies and Future Directions. London, England: John Wiley & Sons; 1994:199-210
47. Dassa D, Kaladjian A, Azorin JM, et al. Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry 1993;163:822-824
48. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-429
49. Sackheim HA, Prudie J, Devanand DP. Treatment of resistant depression with electroconvulsive therapy. In: Tasman A, Goldfinger S. Kaufman CA, eds. American Psychiatry Press Review of Psychiatry, Vol 9. Washington, DC: American Psychiatric Press; 1990:91-115
50. Sackheim HA. Continuation therapy following ECT: directions for future research. Psychopharmacol Bull 1994;30:501-521
51. Sackheim HA, Prudic J, Devanand DP, et al. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 1990;10:96-104
52. Shapira B, Gorfine M, Lerer B. A prospective study of lithium continuation therapy in depressed patients who have responded to electroconvulsive therapy. Convuls Ther 1995;11:80-85
53. Petrides G, Dhossche D, Fink M, et al. Continuation ECT: relapse prevention in affective disorders. Convuls Ther 1994;10:189-194
54. Phillips KA, Nierenberg AA. The assessment and treatment of refractory depression. J Clin Psychiatry 1994:55(2, suppl):20-26